We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma

This study is currently recruiting participants.
Verified January 2017 by International Extranodal Lymphoma Study Group (IELSG)
Sponsor:
ClinicalTrials.gov Identifier:
NCT03031483
First Posted: January 25, 2017
Last Update Posted: May 1, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
International Extranodal Lymphoma Study Group (IELSG)
  Purpose
Patients with lymphoid tissue lymphoma mucosa-associated (MALT) for which the standard treatments with radiotherapy, chemotherapy and / or immunotherapy show lack of efficacy

Condition Intervention Phase
Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Drug: clarithromycin and lenalidomide Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description:
Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial Addressing Feasibility and Activity of Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma

Resource links provided by NLM:


Further study details as provided by International Extranodal Lymphoma Study Group (IELSG):

Primary Outcome Measures:
  • Tumor response assessment [ Time Frame: During the active treatment period after the 3rd cycles of both drugs administration ]
    The primary outcome measure is tumour response assessed according to the Revised Response Criteria for Malignant Lymphoma, either clinically (including appropriate imaging procedures) or endoscopically and histologically (in patients affected by gastric lymphoma, according to the GELA scoring system).


Secondary Outcome Measures:
  • Adverse Events assessments [ Time Frame: During the active treatment period ]
    1. Treatment-emergent adverse events (AEs) incidence, severity and relationship to study treatment.
    2. Time from first IMP administration to assessment of disease progression or death due to any cause, whichever occurs earlier.


Estimated Enrollment: 68
Actual Study Start Date: April 3, 2017
Estimated Study Completion Date: February 2029
Estimated Primary Completion Date: February 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Experimental: clarithromycin and lenalidomide
CLARITHROMYCIN: daily orally administration in cycles of 28 days; 500mg film-coated tablets LENALIDOMIDE: every cycle of treatment lasts 28 days; daily orally administration is of 21 consecutive days with a week of rest. 20mg capsule hard. The maximum treatment duration is 12 months.
Drug: clarithromycin and lenalidomide

Each treatment course will consist of:

Oral Lenalidomide (Revlimid) once daily for 21 days at a dose 20 mg; in case of drug-related adverse events the dose can be reduced to 15 and 10 mg/day; Oral Clarithromycin 500 mg twice daily for 28 days. Courses will be repeated every 28 days. After the first 3 courses patients with stable disease or better response will be given another three courses. Patients with complete remission or disease progression after 6 courses will be taken off study, while patients with partial response or stable disease will receive 3 further courses of treatment. Again, patients with complete response or disease progression will stop therapy, while patients with partial response/stable disease will receive 3 further courses up to a maximum of 12 courses in total.


  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically verified diagnosis of MALT lymphoma arising at any extranodal site
  • Disease refractory to or in first or greater relapse after prior radiotherapy and/ or chemotherapy and/or immunotherapy
  • Measurable or non-measurable lesions where the response is nevertheless evaluable by non-imaging means (e.g., gastric or bone marrow infiltrations)
  • Ann Arbor Stage I-IV
  • ECOG performance status of 0, 1 or 2
  • Age ≥ 18 years
  • Life expectancy of at least 3 months
  • Adequate haematological status: ANC (absolute neutrophil count [segmented + bands]) ≥1.0 x 109/L, platelet count ≥ 75 x 109/L , haemoglobin ≥8 g/dL.
  • Adequate cardiac, renal and liver function tests (LVEF > 40%, serum creatinine < 2.5 mg/dl, ALAT or ASAT < 2.5 x upper limit of normal range, alkaline phosphatase < 2.5 x upper limit of normal range, serum bilirubin < 2.0 mg/dl)
  • Patient must be willing and able to comply with the protocol for the entire study duration
  • Female patients of childbearing potential must agree to use, and be able to comply with, effective contraception and agree to have medically supervised pregnancy tests prior to starting the study treatment and during therapy
  • Male patients must agree to always use a condom during any sexual contact with females of reproductive potential and agree to not donate sperm while taking lenalidomide
  • Patient must agree to abstain from donating blood while taking study drug therapy
  • Patient must agree not to share study medication with another person and to return all unused study drug to the investigator
  • Patient must be willing and able to comply with the protocol
  • Patient must be capable of understanding

Exclusion Criteria:

  • Lymphoma histology other than MALT lymphoma or MALT lymphoma with a diffuse large cell lymphoma ("high grade lymphoma") component
  • Use of any investigational agent within 28 days prior to initiation of treatment
  • History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix within the last 5 years unless in complete remission since at least 3 years
  • Dependency on red blood cell and/or platelet transfusions
  • HBsAg positivity
  • Evidence of central nervous system involvement
  • A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
  • Severe peripheral polyneuropathy
  • Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months and/or long QT-syndrome
  • HIV seropositivity
  • Presence of active opportunistic infections
  • Pregnancy or lactation
  • Uncontrolled diabetes mellitus
  • Pre-existing thromboembolic conditions at study entry
  • Known hypersensitivity to thalidomide or lenalidomide or macrolide antibiotics
  • Presence of any contraindication reported on the Summary of Product Characteristics (SmPC) of Clarithromycin
  • Hypersensitivity to any active principle and/or any excipient according to the contraindications reported in the SmPC of clarithromycin and in the Investigator's Brochure (IB) of lenalidomide
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03031483


Contacts
Contact: Andrès Ferreri, MD +41 02 2643 ext 7649 ferreri.andres@hsr.it
Contact: Markus Raderer, MD markus.raderer@meduniwien.ac.at

Locations
Austria
Medical University of Vienna Not yet recruiting
Vienna, Austria
Contact: Markus Raderer, MD         
Italy
A.O. Spedali Civili di Brescia Recruiting
Brescia, Italy, 25123
Contact: Giuseppe Rossi, MD         
IRCCS Ospedale San Raffaele Recruiting
Milan, Italy, 20132
Contact: Andrés Ferreri, MD         
Fondazione IRCCS - Istituto Nazionale dei Tumori Recruiting
Milan, Italy, 20133
Contact: Liliana Devizzi, MD         
Fondazione IRCCS - Policlinico San Matteo Not yet recruiting
Pavia, Italy, 27100
Contact: Luca Arcanini, MD         
Università degli Studi di Roma La Sapienza Not yet recruiting
Rome, Italy, 00185
Contact: Alessandro Pulsoni, MD         
Ospedale di Circolo e Fondazione Macchi di Varese Recruiting
Varese, Italy, 21100
Contact: Michele Merli, MD         
AOUI Verona - Ospedale Borgo Roma Not yet recruiting
Verona, Italy, 37134
Contact: Achille Ambrosetti, Prof         
Azienda Sanitaria ULSS 6 - Ospedale S.Bortolo Not yet recruiting
Vicenza, Italy, 36100
Contact: Carlo Visco, MD         
Spain
Instituto de Enfermedades Hematológicas y Oncológicas Not yet recruiting
Barcelona, Barcellona, Spain, 08036
Contact: Armando Lopez Guillermo, MD         
Institut Català D'Oncologia Hospital Duran I Reynals Not yet recruiting
Hospitalet de Llobregat, Barcelona, Spain, 08908
Contact: Eva Domingo Domenench, MD         
Hospital del Mar Not yet recruiting
Barcelona, Spain, 08003
Contact: Antonio Salar, MD         
MD Anderson Cancer Center Not yet recruiting
Madrid, Spain, 28033
Contact: Carlos Montalban, MD         
Hospital Universitario Not yet recruiting
Salamanca, Spain, 37007
Contact: Norma Gutierrez, MD         
Sponsors and Collaborators
International Extranodal Lymphoma Study Group (IELSG)
Investigators
Study Director: Emanuele Zucca, Prof International Extranodal Lymphoma Study Group
  More Information

Responsible Party: International Extranodal Lymphoma Study Group (IELSG)
ClinicalTrials.gov Identifier: NCT03031483     History of Changes
Other Study ID Numbers: IELSG40
First Submitted: January 23, 2017
First Posted: January 25, 2017
Last Update Posted: May 1, 2017
Last Verified: January 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Lymphoma
Lymphoma, B-Cell, Marginal Zone
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Lenalidomide
Thalidomide
Clarithromycin
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Immunosuppressive Agents
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors